Trastuzumab Deruxtecan scores two wins in HER2-positive early breast cancer

(MedPage Today) – Berlin – The antibody-conjugated drug trastuzumab deruxtecan (ADC) (T-DXd, Enhertu) has achieved impressive results in various HER2-positive early-stage breast cancers in consecutive randomized clinical trials. in…